Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 27.9% during trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.28. 1,401,717 shares changed hands during trading, an increase of 100% from the average session volume of 700,531 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Performance
The stock has a market cap of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20. The firm has a fifty day moving average price of C$0.11 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is the Dow Jones Industrial Average (DJIA)?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Are Earnings Reports?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- What Are Dividend Champions? How to Invest in the Champions
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
